Post by stcks on Aug 3, 2017 17:39:16 GMT
Array BioPharma Inc. has added a news release to its Investor Relations website.
Title: Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 On August 9, 2017
Date(s): 8/3/2017 11:50 AM
Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 On August 9, 2017
August 03, 2017
BOULDER, Colo., Aug. 3, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the fourth quarter and full year of fiscal 2017 and hold a conference call to discuss those results on Wednesday, August 9, 2017. Ron Squarer, Chief Executive Officer, will lead the call.
Date:
Wednesday, August 9, 2017
Time:
9:00 a.m. Eastern Time
Toll-Free:
(844) 464-3927
Toll:
(765) 507-2598
Pass Code:
44703107
Array BioPharma. (PRNewsFoto/Array BioPharma Inc.) (PRNewsFoto/)
Webcast, including Replay and Conference Call Slides:
edge.media-server.com/m/p/af6yqtav
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).
CONTACT:
Tricia Haugeto
Array BioPharma Inc.
(303) 386-1193
thaugeto@arraybiopharma.com
View original content with multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-fourth-quarter-and-full-year-of-fiscal-2017-on-august-9-2017-300499225.html
SOURCE Array BioPharma
Title: Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 On August 9, 2017
Date(s): 8/3/2017 11:50 AM
Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 On August 9, 2017
August 03, 2017
BOULDER, Colo., Aug. 3, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the fourth quarter and full year of fiscal 2017 and hold a conference call to discuss those results on Wednesday, August 9, 2017. Ron Squarer, Chief Executive Officer, will lead the call.
Date:
Wednesday, August 9, 2017
Time:
9:00 a.m. Eastern Time
Toll-Free:
(844) 464-3927
Toll:
(765) 507-2598
Pass Code:
44703107
Array BioPharma. (PRNewsFoto/Array BioPharma Inc.) (PRNewsFoto/)
Webcast, including Replay and Conference Call Slides:
edge.media-server.com/m/p/af6yqtav
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).
CONTACT:
Tricia Haugeto
Array BioPharma Inc.
(303) 386-1193
thaugeto@arraybiopharma.com
View original content with multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-fourth-quarter-and-full-year-of-fiscal-2017-on-august-9-2017-300499225.html
SOURCE Array BioPharma
